Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.
about
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathyTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviewsCorticosteroids for chronic inflammatory demyelinating polyradiculoneuropathyManufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacyTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeTreatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.Indications and safety of intravenous and subcutaneous immunoglobulin therapy.Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010.Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go.Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.Economic costs and quality of life in chronic inflammatory neuropathies in southeast England.Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.An analysis of AAN′s evidence-based guideline for IVIg use in neurologic disorders: Provider impact and payer perspectives.Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy.Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection.
P2860
Q24186751-C4B1830C-E5EB-4D6B-B469-FAD34168AECAQ24201434-8B8AC54A-2B8B-454F-9AC6-8DB9B188D9E9Q24201662-1FEBE5DB-D1EA-4A5D-9D0B-A8C409DEC779Q27027732-ABA4D180-E18A-40B7-9D4D-958F2DABE0FBQ30397454-99D182D4-CBCB-4835-B3E4-6C7C26B5C0CBQ33419638-ABBE30D4-8BAC-4254-A33A-D1DBE76AD411Q37557375-DC6092F3-94B3-420A-B065-AC9361E483D3Q37877259-87E2BAE8-1BB1-46C8-AB92-C6CF4A0B1C42Q37895536-7D97C73E-E6D8-45C9-8B69-F99F6290555DQ38194642-22171F63-9D9C-46BF-9E00-720079D5D7D9Q39823028-9054072F-FE49-457D-AB88-A7D27F03A471Q43620332-6DB50A12-7C1A-4877-B0FC-4BBADB8F9887Q46887163-50132BB9-5128-450D-B1FD-B66C0540D1AAQ49536267-B6FEE2AB-582A-46E4-A4B4-86D3944A1A0FQ50231116-952DD220-FD19-4FBA-9FA0-B33507E3F7ADQ53646810-CFEDE9A0-2CF2-4E2D-AA5A-56998A7062C2Q55516782-56CB75DC-83B5-40DF-9CED-6123303F30CF
P2860
Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cost-utility of Intravenous Im ...... lyneuropathy (CIDP) in Canada.
@ast
Cost-utility of Intravenous Im ...... lyneuropathy (CIDP) in Canada.
@en
type
label
Cost-utility of Intravenous Im ...... lyneuropathy (CIDP) in Canada.
@ast
Cost-utility of Intravenous Im ...... lyneuropathy (CIDP) in Canada.
@en
prefLabel
Cost-utility of Intravenous Im ...... lyneuropathy (CIDP) in Canada.
@ast
Cost-utility of Intravenous Im ...... lyneuropathy (CIDP) in Canada.
@en
P2093
P2860
P356
P1476
Cost-utility of Intravenous Im ...... lyneuropathy (CIDP) in Canada.
@en
P2093
Colin Chalk
Daria O'Reilly
Gord Blackhouse
Jean-Eric Tarride
Kaitryn Campbell
Kathryn Gaebel
Mitchell Levine
Nazila Assasi
Ron Goeree
P2860
P2888
P356
10.1186/1478-7547-8-14
P577
2010-06-17T00:00:00Z
P5875
P6179
1019120067